Health Trials

The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD

ConditionsT2DMMAFLD
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-75
SponsorThe Fourth Affiliated Hospital of Zhejiang University School of Medicine

About this trial

To compare the efficacy and safety of the combination of alogliptin and actoplus met with that of actoplus met alone in improving the glucose and lipid metabolism and pancreatic function in T2DM patients complicated with MAFLD.

Eligibility criteria

Qualifiers

Clinical diagnosis of T2DM

Clinical diagnosis of MAFLD

HbA1c: 6.5-9.5%

BMI: 19-35 kg/m2

Disqualifiers

Severe infections, surgeries and other emergency

Other types of diabetes

Severe cardiovascular, brain, liver and kidney disorders

Malignant tumor

Trial design

Treatments tested in this trial

  • alogliptin and actoplus met
  • actoplus met

Treatment groups

80 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Lead sponsor

Source ClinicalTrials.gov